Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
391.59
-3.10 (-0.79%)
After Hours: 391.59 0.00 (0.00%)
Nov 17, 4:22PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 390.52 - 396.36
52 week 340.09 - 543.55
Open 393.08
Vol / Avg. 669,073.00/882,577.00
Mkt cap 42.07B
P/E 35.58
Div/yield     -
EPS 11.01
Shares 105.53M
Beta 1.56
Inst. own 71%
Jan 31, 2018
Q4 2017 Regeneron Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 28, 2017
Regeneron Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 4:00PM EST - Add to calendar
Nov 8, 2017
Q3 2017 Regeneron Pharmaceuticals Inc Earnings Release
Nov 8, 2017
Q3 2017 Regeneron Pharmaceuticals Inc Earnings Call - Webcast
Sep 13, 2017
Regeneron Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
Sep 11, 2017
Regeneron Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 25.88% 18.42%
Operating margin 37.31% 27.38%
EBITD margin - 29.53%
Return on average assets 18.53% 14.23%
Return on average equity 26.92% 22.10%
Employees 5,400 -
CDP Score - B

Address

777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 87
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Daniel P. Van Plew Executive Vice President, General Manager - Industrial Operations and Product Supply
Age: 44
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Executive Vice President - Research and Development
Age: 60
Bio & Compensation  - Reuters
Robert J. Terifay Executive Vice President - Commercial
Age: 57
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
Michael Aberman M.D. Senior Vice President - Strategy and Investor Relation
Age: 46
Bio & Compensation  - Reuters
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 60
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. President and Chief Scientific Officer - Regeneron, Director
Age: 57
Bio & Compensation  - Reuters